Genzyme's surgical mesh gets US clearance:
This article was originally published in Clinica
Genzyme Surgical Products has received 510(k) clearance from the US FDA to market its Sepramesh Biosurgical Composite for use in hernia repair procedures. The surgical mesh is designed to be sutured in place along the abdominal wall providing support and strength to the hernia repair. Sepramesh contains a bioresorbable barrier that separates the mesh from underlying tissue and organ surfaces to minimise attachment to the mesh. This offers significant advantages over traditional mesh products, the Cambridge, Massachusetts-based company said.
You may also be interested in...
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.